Favorable Geographical Position
Inexhaustible Innovation Vigor
Service-oriented Governmental Agencies
International Living Environment
Healthcare & elderly care
Joint capital cooperation
Construction of biological fermentation, extraction and synthetic production of multi-purpose production lines, products include antifungal drugs: mooring Finn net card, mika fragrance static, Anidulafungin, and other types of immune inhibitors antitumor drugs: sirolimus, tacrolimus, according to the dimension of therapy, for sirolimus, super antibiotic drugs: including the daptomycin, Ramoplanin, and other products. At the same time, production lines for 10 million anti-tumor freeze-dried powder injections will be built.
The project is led by Yuan Yi, winner of Shandong Province's "Returned Overseas Students Entrepreneur Award", who has obtained products through microbial fermentation, extraction, synthesis and other technologies and through various processes such as genetic modification, microfiltration, ultrafiltration, and nanofiltration. The products are mainly used in difficult and high-incidence tumor treatment, organ transplantation, anti-super virus and other aspects, filling the domestic gaps in many drugs. Currently, it has won 2 patents for inventions and 10 patents for utility models. The biomedical project achieved fruitful results in 2017. Three products developed by the company have obtained registration certificates in China and three products have obtained European CEP certificates. The products have officially entered the European market. It won the titles of "Provincial Enterprise Technology Center" and "National Hi-tech Enterprise", and passed the special project review of the National Development and Reform Commission to enhance the core competitiveness of manufacturing industry. The promotion of the products of this project can change the current situation that domestic anti-tumor and immunosuppressive drugs and other high-end drugs rely mainly on import, and at the same time reduce the price of drugs and the burden on patients. After the project is put into production, the annual sales revenue will be RMB 6 billion and the profit tax will be RMB 1.2 billion.
Wang Xingwen and Liu Fuhai 0530-6226266